Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01820364
Title LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

melanoma

Therapies

Binimetinib + Encorafenib

Encorafenib + Ribociclib

Buparlisib + Encorafenib

Encorafenib + Infigratinib

Capmatinib + Encorafenib

Age Groups: adult
Covered Countries USA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Sarah Cannon Research Institute Onc Dept Nashville Tennessee 37203 United States Details
Novartis Investigative Site East Melbourne Victoria 3002 Australia Details
Novartis Investigative Site Edmonton Alberta T6G 1Z2 Canada Details
Novartis Investigative Site Heidelberg 69120 Germany Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Zuerich 8091 Switzerland Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field